Compared side by side
Semaglutide vs BPC-157: how they differ
The short answer
They do different jobs: semaglutide is a weekly GLP-1 receptor agonist, FDA-approved for type 2 diabetes and weight management, and BPC-157 is a peptide derived from a protein in human gastric juice that, in animal studies, protects the gut lining and speeds tendon, ligament and muscle repair. Semaglutide averaged about 15% weight loss at 68 weeks in its main trial; BPC-157’s human studies so far are three small uncontrolled pilots. Commonly reported: nausea worst in the first days after each semaglutide dose step, and a calmer gut on BPC-157, which the library lists beside semaglutide for GI support.
Side by side
| Compared | Semaglutide | BPC-157 |
|---|---|---|
| Category | Metabolic & GLP-1 | Healing & recovery |
| Also known as | Ozempic, Wegovy | Body Protection Compound 157, BPC157 |
| What it is | A GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying. | A peptide derived from a protective protein in your stomach. |
| How it works | GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects. | Synthetic pentadecapeptide derived from a protein in human gastric juice. In animal studies it promotes angiogenesis, speeds tendon, ligament and muscle healing, modulates dopamine and serotonin systems, and protects the gut lining. |
| Commonly reported | The constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial. | Faster recovery from tendon and ligament injuries, and a calmer gut. It's one of the most widely used peptides in the community; the human studies so far are three small uncontrolled pilots. |
| Studied range | FDA label: 0.25–2.4 mg, starting dose 0.25 mg. | Research range: 200–500 mcg. Studied in research — not a recommendation. |
| How often | Weekly SubQ | Once or twice daily |
| Half-life | ~1 week (FDA label) | ~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes) |
| Route | SubQ injection | SubQ injection, IM injection, Oral (less studied) |
| Typical run | FDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers. | Typically 4–12 weeks. Many run until injury resolves then stop. Some run indefinitely at lower doses. Opinions vary widely. |
| Evidence | Established: clinical trials or FDA-approved use exists | Emerging: primarily preclinical / limited human data |
| Common side effects | Nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk | Nausea (rare), injection site irritation, vivid dreams, dizziness |
- Category
- SemaglutideMetabolic & GLP-1
- BPC-157Healing & recovery
- Also known as
- SemaglutideOzempic, Wegovy
- BPC-157Body Protection Compound 157, BPC157
- What it is
- SemaglutideA GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying.
- BPC-157A peptide derived from a protective protein in your stomach.
- How it works
- SemaglutideGLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects.
- BPC-157Synthetic pentadecapeptide derived from a protein in human gastric juice. In animal studies it promotes angiogenesis, speeds tendon, ligament and muscle healing, modulates dopamine and serotonin systems, and protects the gut lining.
- Commonly reported
- SemaglutideThe constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial.
- BPC-157Faster recovery from tendon and ligament injuries, and a calmer gut. It's one of the most widely used peptides in the community; the human studies so far are three small uncontrolled pilots.
- Studied range
- SemaglutideFDA label: 0.25–2.4 mg, starting dose 0.25 mg.
- BPC-157Research range: 200–500 mcg. Studied in research — not a recommendation.
- How often
- SemaglutideWeekly SubQ
- BPC-157Once or twice daily
- Half-life
- Semaglutide~1 week (FDA label)
- BPC-157~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes)
- Route
- SemaglutideSubQ injection
- BPC-157SubQ injection, IM injection, Oral (less studied)
- Typical run
- SemaglutideFDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers.
- BPC-157Typically 4–12 weeks. Many run until injury resolves then stop. Some run indefinitely at lower doses. Opinions vary widely.
- Evidence
- SemaglutideEstablished: clinical trials or FDA-approved use exists
- BPC-157Emerging: primarily preclinical / limited human data
- Common side effects
- SemaglutideNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk
- BPC-157Nausea (rare), injection site irritation, vivid dreams, dizziness
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Semaglutide
- Day 1–28 · 0.25 mg Gut is adapting
- Day 29–56 · 0.5 mg Appetite shifts are real now
- Day 57–112 · 1 mg Clinically useful weight loss kicks in
- Day 113–140 · 1.7 mg Max submaximal step
- Day 141–364 · 2.4 mg Full dose — the working dose
- Day 365+ Plateau territory — new baseline
BPC-157
- Day 1–7 Week one: early hints, for some
- Day 7–14 Pain often starts to ease
- Day 14–21 Pain often eases by week three
- Day 21–28 Many report a calmer gut
- Day 28–42 The slower part of repair
- Day 42–56 Six weeks in: taking stock
- Day 84+ Past week 12, the data runs thin
Together or one or the other
Semaglutide and BPC-157 are a common stack: semaglutide lists BPC-157 among its common stacks.
Community · Semaglutide
Why people add BPC-157 to Sema
Sema titration comes with GI symptoms, and BPC-157, first studied as a stomach-protecting peptide, is added to ease them. Commonly reported: fewer GI side effects in the first weeks after each step-up.
Questions people ask
How long do semaglutide and BPC-157 last?
The half-life of semaglutide is ~1 week (FDA label). The half-life of BPC-157 is ~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes).
How often are semaglutide and BPC-157 taken?
Semaglutide: weekly SubQ. Route: SubQ injection. BPC-157: once or twice daily. Routes: SubQ injection, IM injection, oral (less studied).
How are semaglutide and BPC-157 dosed in research?
The FDA label range for semaglutide is 0.25–2.4 mg, with a 0.25 mg starting dose. The research range for BPC-157 is 200–500 mcg. Studied in research — not a recommendation.
What are the common side effects of semaglutide and BPC-157?
For semaglutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk. For BPC-157: nausea (rare), injection site irritation, vivid dreams, dizziness.
Are semaglutide and BPC-157 taken together?
Semaglutide and BPC-157 are a common stack: semaglutide lists BPC-157 among its common stacks. Sema titration comes with GI symptoms, and BPC-157, first studied as a stomach-protecting peptide, is added to ease them. Commonly reported: fewer GI side effects in the first weeks after each step-up.